Cellectar Biosciences公司最新发布的2B期Clover Wam研究12个月随访数据证实,其核心候选药物Iopofosine I 131在治疗复发/难治性华氏巨球蛋白血症(R/R WM)领域展现出持久的治疗反应与显著的临床疗效。
长期随访结果进一步验证了该放射性药物治疗方案的潜力,为这类罕见血液恶性肿瘤患者提供了新的希望。数据显示,接受治疗的患者在12个月观察期内持续产生深度缓解,药物安全性特征与早期研究结果保持一致。
Cellectar Biosciences公司最新发布的2B期Clover Wam研究12个月随访数据证实,其核心候选药物Iopofosine I 131在治疗复发/难治性华氏巨球蛋白血症(R/R WM)领域展现出持久的治疗反应与显著的临床疗效。
长期随访结果进一步验证了该放射性药物治疗方案的潜力,为这类罕见血液恶性肿瘤患者提供了新的希望。数据显示,接受治疗的患者在12个月观察期内持续产生深度缓解,药物安全性特征与早期研究结果保持一致。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.